This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC). Continuing our discussion with Martin ...
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or ...
The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...
Sugemalimab application seeks approval for unresectable stage 3 NSCLC post-chemoradiotherapy, supported by phase 3 GEMSTONE-301 study data. The study showed a 36% reduction in disease progression risk ...
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results